Know Cancer

forgot password

Meso BioMatrix Acellular Peritoneum Matrix Breast Reconstruction Feasibility Trial

Phase 1/Phase 2
21 Years
Open (Enrolling)
Breast Cancer, Breast Reconstruction

Thank you

Trial Information

Meso BioMatrix Acellular Peritoneum Matrix Breast Reconstruction Feasibility Trial

Following mastectomy, women may elect to have breast reconstruction with autologous tissue
or breast implants. Two-stage, tissue expander assisted breast reconstruction is one of the
common surgical methods that could be selected to reconstruct the breast. This method
either begins immediately after mastectomy (known as immediate breast reconstruction) or at
some time afterward (known as delayed breast reconstruction). Historically, surgeons placed
a tissue expander followed by the breast implant either completely or partially under the
pectoralis muscle. However, this method of breast reconstruction has been associated with
less favorable aesthetic outcomes.

Recently, surgeons started adding a surgical mesh derived from human cadaver skin during
breast reconstruction procedures. In summary, during the first stage of the breast
reconstruction, the plastic surgeon releases the pectoralis muscle from the chest wall. The
surgeon then attaches the surgical mesh to the pectoralis muscle and to the chest wall just
below the breast. This is done to create a pocket for the tissue expander. The tissue
expander is implanted in the pocket and partially inflated. The tissue expander is
gradually filled with saline over several weeks or months. Once the desired breast volume
has been achieved, the second stage of the reconstruction takes place. In the second stage,
the tissue expander is removed and replaced with a permanent saline or silicone gel breast

Use of the human cadaver skin surgical mesh during breast reconstruction has been associated
with less pain, fewer tissue expansion visits and improved aesthetic outcomes. However, the
human cadaver skin surgical mesh adds significant cost to the procedure and some surgeons
have reported an increased rate of post-operative complications.

Over the last 10 years, a number of surgical mesh devices have been cleared by the U.S. Food
& Drug Administration (FDA) for the reinforcement and repair weak soft tissue or became
available as tissue grafts from human donors. Some surgeons have published their experience
with a number of these surgical mesh devices for breast reconstruction. However, at
present, no surgical mesh device is approved or cleared by the FDA for use in breast

The Meso BioMatrix device was recently cleared by the FDA for reinforcement and repair of
weak soft tissue. It is a surgical mesh device that is made from pig peritoneum, the tissue
that lines the abdominal cavity. The tissue is thoroughly cleaned and sterilized before
use. When implanted, the Meso BioMatrix device provides structural and mechanical support
to weak soft tissue during the healing process.

This clinical trial is a feasibility trial. A feasibility trial is a clinical trial in
which a device is being studied in a small group of people for a new use. Since the Meso
BioMatrix device is not cleared specifically for use in breast reconstruction, it is
considered investigational and must be studied in a controlled, step-wise series of clinical
trials. Therefore, the results of this trial, if successful, may be used to design a larger
clinical trial in the future.

Inclusion Criteria:

- Non-smoker

- Undergoing unilateral or bilateral, two-stage, tissue expander-assisted breast

- Life expectancy greater than 18 months

- Agreement to return for the trial required follow-up visits

Exclusion Criteria:

- Body mass index ≥ 35

- Prior reconstructive breast surgery, breast augmentation, mastopexy or reduction

- History of chronic corticosteroid use

- Type I Diabetes

- History of radiation therapy to the chest

- Treatment of pre-operative induction chemotherapy for breast cancer

- Pregnancy

- Participating in another investigational drug or device trial that has not completed
the follow-up period

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Rate of breast related adverse events

Outcome Time Frame:

18 months

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

October 2012

Completion Date:

Related Keywords:

  • Breast Cancer
  • Breast Reconstruction
  • Meso BioMatrix
  • Breast
  • Breast Cancer
  • Breast Reconstruction
  • Mastectomy
  • Biologic Mesh
  • Breast Neoplasms



The University of ChicagoChicago, Illinois  60637
Long Island Plasic Surgical Group, PCGarden City, New York  
Long Island Plastic Surgical Group, PCManhasset, New York